---
title: "ABPRO HOLDINGS INC C/WTS 12/11/2029 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.05"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252915169.md"
datetime: "2025-08-13T20:19:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252915169.md)
  - [en](https://longbridge.com/en/news/252915169.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252915169.md)
---

# ABPRO HOLDINGS INC C/WTS 12/11/2029 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.05

EPS: As of FY2025 Q2, the actual value is USD -0.05.

### Segment Revenue

-   The company did not generate revenue during the three and six months ended June 30, 2025, and 2024.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended June 30, 2025, was $2,984,000, compared to $2,440,000 for the same period in 2024, representing a 22% increase.
-   **Research and Development Expenses**: Decreased by 62% to $313,000 for the three months ended June 30, 2025, from $827,000 in the same period in 2024.
-   **General and Administrative Expenses**: Increased by 29% to $1,948,000 for the three months ended June 30, 2025, from $1,513,000 in the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, was $3,105,000, a decrease from $4,218,000 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the six months ended June 30, 2025, was $2,142,000, compared to $3,559,000 for the same period in 2024.

### Unique Metrics

-   **Convertible Notes**: The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., issuing convertible promissory notes totaling $5,000,000, with $3,000,000 issued in November 2024 and $2,000,000 in June 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to initiate clinical trials for ABP-102 in the first half of 2026, focusing on HER2+ solid tumors, and for ABP-201, depending on future funding availability.
-   **Non-Core Business**: The company is exploring additional funding through equity and debt financings, collaboration agreements, and research grants to support its operations and strategic initiatives.

### Related Stocks

- [ABPWW.US](https://longbridge.com/en/quote/ABPWW.US.md)

## Related News & Research

- [Meet the Dividend King That's Quietly Crushing the S&P 500 in 2026. Here's Why It's a Buy This August.](https://longbridge.com/en/news/296262501.md)
- [BREAKINGVIEWS-Anthropic’s deceleration has some IPO upside](https://longbridge.com/en/news/296261346.md)
- [Warren Buffett's Successor, Greg Abel, Has 34.7% of Berkshire Hathaway's Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks](https://longbridge.com/en/news/296274565.md)
- [Oil edges up on uncertainty over exports through Hormuz](https://longbridge.com/en/news/296282399.md)
- [Interactive Brokers Is Holding $930 Billion of Customer Money. Here's What That Earns at Today's Rates.](https://longbridge.com/en/news/296319893.md)